Integrated Transcriptomics–Metabolomics Analysis Reveals Biomarkers and Metabolic Dysregulation Characteristics of Parenteral Nutrition–Associated Liver Disease

Why It Matters

Identifying reliable molecular signatures enables earlier diagnosis and targeted treatment of a high‑mortality complication of long‑term parenteral nutrition, addressing a critical gap in liver‑failure care.

Key Takeaways

• Five gene biomarkers identified for PNALD
• Three metabolites linked to disease progression
• Biomarkers correlate with myeloid‑derived suppressor cells
• Integrated transcriptomics‑metabolomics improves target discovery
• Predicted drugs offer potential therapeutic avenues

Pulse Analysis

Parenteral nutrition‑associated liver disease remains a leading cause of morbidity in patients reliant on long‑term intravenous feeding, affecting up to 40% of adults and two‑thirds of neonates. Early biochemical changes often precede overt histological damage, making timely detection essential for preventing irreversible fibrosis or cirrhosis. Traditional diagnostics rely on nonspecific liver enzyme panels, which lack the precision needed to guide personalized interventions, underscoring the demand for robust molecular markers.

In the recent Frontiers in Nutrition study, researchers leveraged high‑throughput RNA‑seq and non‑targeted metabolomics to map the hepatic landscape of PNALD mice. By applying dual machine‑learning filters—LASSO regression and support vector‑machine recursive feature elimination—they distilled 142 differentially expressed genes and 18 metabolites down to five actionable gene signatures and three metabolite candidates. These biomarkers not only clustered within cytokine‑receptor and oxidative‑phosphorylation pathways but also displayed strong associations with immune cell subsets, particularly myeloid‑derived suppressor cells, highlighting a tightly knit inflammatory‑metabolic axis.

The translational impact of these findings is twofold. First, the validated gene and metabolite panels provide clinicians with a more nuanced diagnostic toolkit that could detect PNALD before irreversible damage occurs. Second, in silico drug‑gene interaction analyses revealed existing compounds—such as liarozole and IC14—that may modulate the identified targets, offering a rapid repurposing pathway for therapeutic development. Future work should focus on confirming these markers in human cohorts, dissecting their mechanistic roles, and integrating gut microbiome data to fully elucidate the PNALD network, thereby paving the way for precision medicine approaches in nutritional liver disease.